Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV-Reference-Cited by-同舟云学术

Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV

Published:2022-08-22 Issue:1 Volume:13 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Vergori Alessandra^ORCID,Cozzi Lepri Alessandro,Cicalini Stefania,Matusali Giulia,Bordoni Veronica,Lanini Simone,Meschi Silvia,Iannazzo Roberta,Mazzotta Valentina^ORCID,Colavita Francesca,Mastrorosa Ilaria,Cimini Eleonora,Mariotti Davide^ORCID,De Pascale Lydia,Marani Alessandra,Gallì Paola,Garbuglia AnnaRosa,Castilletti Concetta^ORCID,Puro Vincenzo,Agrati Chiara,Girardi Enrico,Vaia Francesco,Antinori Andrea,Amendola Alessandra,Baldini Francesco,Bellagamba Rita,Bettini Aurora,Bordi Licia,Camici Marta,Casetti Rita,Costantini Sarah,Cristofanelli Flavia,D’Alessio Claudia,D’Aquila Veronica,De Angelis Alessia,De Zottis Federico,de Pascale Lydia,Francalancia Massimo,Fusto Marisa,Gagliardini Roberta,Gramigna Giulia,Grassi Germana,Grilli Elisabetta,Grisetti Susanna,Iafrate Denise,Lapa Daniele,Lorenzini Patrizia,Marani Alessandra,Masone Erminia,Marongiu Stefano,Mondi Annalisa,Notari Stefania,Ottou Sandrine,Paulicelli Jessica,Pellegrino Luca,Pinnetti Carmela,Plazzi Maria Maddalena,Possi Adriano,Sacchi Alessandra,Tartaglia Eleonora,

Abstract

AbstractIn order to investigate safety and immunogenicity of SARS-CoV-2 vaccine third dose in people living with HIV (PLWH), we analyze anti-RBD, microneutralization assay and IFN-γ production in 216 PLWH on ART with advanced disease (CD4 count <200 cell/mm3 and/or previous AIDS) receiving the third dose of a mRNA vaccine (BNT162b2 or mRNA-1273) after a median of 142 days from the second dose. Median age is 54 years, median CD4 nadir 45 cell/mm3 (20–122), 93% HIV-RNA < 50 c/mL. In 68% of PLWH at least one side-effect, generally mild, is recorded. Humoral response after the third dose was strong and higher than that achieved with the second dose (>2 log2 difference), especially when a heterologous combination with mRNA-1273 as third shot is used. In contrast, cell-mediated immunity remain stable. Our data support usefulness of third dose in PLWH currently receiving suppressive ART who presented with severe immune dysregulation.

Funder

Ministero della Salute

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary

Link

https://www.nature.com/articles/s41467-022-32263-7.pdf

Reference53 articles.

1. WHO Coronavirus (COVID19) Dashboard. Available at: https://covid19.who.int.

2. Koff, W. C. et al. Development and deployment of COVID-19 vaccines for those most vulnerable. Sci. Transl. Med. 13, eabd1525 (2021). PMID: 33536277.

3. Lopez Bernal, J. et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N. Engl. J. Med. 385, 585–594 (2021). Epub 2021 Jul 21. PMID: 34289274; PMCID: PMC8314739.

4. Nasreen, S. et al. Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada. medRxiv. 06.28.21259420; https://doi.org/10.1101/2021.06.28.21259420. (2021)

5. Comirnaty and Spikevax: EMA recommendations on extra doses and boosters. Available at: https://www.ema.europa.eu/en/news/comirnaty-spikevax-ema-recommendations-extra-doses-boosters.

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Humoral response after mRNA COVID-19 primary vaccination and single booster dose in people living with HIV compared to controls: A French nationwide multicenter cohort study—ANRS0001s COV-POPART;International Journal of Infectious Diseases;2024-09

2. SARS-CoV-2-specific T-cell responses are induced in people living with human immunodeficiency virus after booster vaccination;Chinese Medical Journal;2024-07-18

3. Bringing optimised COVID-19 vaccine schedules to immunocompromised populations (BOOST-IC): study protocol for an adaptive randomised controlled clinical trial;Trials;2024-07-17

5. SARS-CoV-2 Humoral and Cellular Immune Responses in People Living with HIV;Vaccines;2024-06-16